Want to see SNYR full AI Analyst Report?
SNYR Stock Chart & Stats
$1.63
$0.16(3.75%)
At close: 4:00 PM EST
$1.63
$0.16(3.75%)
Day’s Range― - ―
52-Week Range$0.19 - $4.00
Previous CloseN/A
Volume8.10K
Average Volume (3M)136.07K
Market Cap
$2.92M
Enterprise Value$29.63M
Total Cash (Recent Filing)$292.12K
Total Debt (Recent Filing)$27.75M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.60
Shares Outstanding14,899,883
10 Day Avg. Volume89,526
30 Day Avg. Volume136,069
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.78
Price to Sales (P/S)0.60
P/FCF Ratio-7.00
Enterprise Value/Market Cap10.16
Enterprise Value/Revenue1.07
Enterprise Value/Gross Profit1.64
Enterprise Value/Ebitda-3.41
Forecast
1Y Price Target
$3.75Price Target Upside130.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.13
Revenue Forecast (FY)$33.67M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~67% gross margin is a durable structural strength for a medical distributor: it indicates strong pricing or product mix that creates substantial gross profit per dollar of revenue. This margin provides buffer to absorb SG&A and supports a pathway to recovery if operating costs and cash burn are controlled over months.
Committed Equity Financing LineAccess to an up-to-$36M equity line across 24 months materially increases liquidity runway and capital flexibility. For a cash-burning company, this structural financing reduces immediate solvency pressure, enabling operational fixes or listing compliance actions without requiring immediate asset sales.
Board & Shareholder Support For Governance ActionsShareholder approval of management slate, equity-plan amendments, and reverse-split authority signals governance continuity and investor willingness to permit strategic tools. Stable board oversight and explicit authorization for compliance levers support consistent execution of turnaround plans over the coming months.
Bears Say
Severe Leverage And Negative EquityDebt materially exceeds the asset base and equity is consistently negative, creating acute solvency and refinancing risk. High leverage limits access to attractive financing, increases creditor and covenant pressure, and amplifies the probability that corrective actions (asset sales or dilutive financing) will be needed in the medium term.
Persistent Cash Burn And Deep LossesDeclining revenue, a deeply negative net margin, and sustained negative operating and free cash flow indicate the company is consuming cash rather than generating it. This structural earnings and cash-flow weakness constrains reinvestment, debt reduction, and margin recovery absent durable operational improvement or external capital.
Listing Compliance & Dilution RiskA Nasdaq minimum-bid-price notice creates concrete listing risk and forces structural remedies (reverse split or other actions). Combined with an expanded equity plan and active equity line, this raises sustained dilution risk and execution uncertainty, which can impair liquidity, investor confidence, and strategic optionality over months.
Synergy CHC News
SNYR FAQ
What was Synergy CHC’s price range in the past 12 months?
Synergy CHC lowest stock price was $0.18 and its highest was $4.00 in the past 12 months.
What is Synergy CHC’s market cap?
Synergy CHC’s market cap is $2.92M.
When is Synergy CHC’s upcoming earnings report date?
Synergy CHC’s upcoming earnings report date is Nov 12, 2026 which is in 124 days.
How were Synergy CHC’s earnings last quarter?
Currently, no data Available
Is Synergy CHC overvalued?
According to Wall Street analysts Synergy CHC’s price is currently Undervalued.
Does Synergy CHC pay dividends?
Synergy CHC does not currently pay dividends.
What is Synergy CHC’s EPS estimate?
Synergy CHC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synergy CHC have?
Synergy CHC has 14,899,883 shares outstanding.
What happened to Synergy CHC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synergy CHC?
Currently, no hedge funds are holding shares in SNYR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synergy CHC
Synergy CHC Corp. operates as a distributor of diverse consumer health, beauty, and lifestyle merchandise across the United States, Canada, and the United Kingdom. The company's brand portfolio features FOCUSfactor, specializing in nutritional supplements aimed at enhancing brain function. It also offers the Flat Tummy line, which includes a range of wellness and fashion items such as specialty teas, meal replacement shakes, lollipops, dietary aids, apparel, and exercise accessories. Furthermore, under the Hand MD brand, Synergy CHC Corp. provides anti-aging skincare products, encompassing serums and creams designed for exfoliation, skin repair, and rehydration, as well as hand hygiene products like soaps and sanitizers. These goods are made available to consumers through conventional retail partners and significant television advertising campaigns. The company's skincare range, in particular, is also sold directly via online platforms. Founded in 2010, the firm was originally named Synergy Strips Corp. and rebranded to Synergy CHC Corp. in August 2015. Its primary business operations are based in Westbrook, Maine.
SNYR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture. Material one-time charges (notably a $6.66M bad debt allowance, inventory and media write-offs, and a ~$2.9M license revenue reversal) produced large GAAP losses and pushed operating expenses and adjusted EBITDA down. Offsetting these negatives, management highlighted meaningful strategic progress: beverage early traction (Q1 2026 > all of 2025), Mexico subsidiary and Costco Mexico entry, expanded Kroger distribution, stronger cash and working capital, and management’s contention that normalized gross margins are healthy. Operational risks remain (Flat Tummy weakness, TV advertising not restarted, and elevated inventory levels), but management frames many of the financial setbacks as one-time items with a path to improved normalized performance. Overall, positives and negatives are balanced.View all SNYR earnings summariesSNYR Stock 12 Month Forecast
Average Price Target
$3.75
▲(130.06% Upside)
Technical Analysis
Ownership Overview
34.42% Insiders
4.54% Mutual Funds
0.07% Other Institutional Investors
60.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---